Avtor/Urednik		Osrajnik, Ilonka; Letonja, Saša; Debevec, Miha
Naslov		Kemoterapija drobnoceličnega pljučnega raka: naše izkušnje s kombinacijo ifosfamid-etopozid
Prevedeni naslov		Chemotherapy for small cell lung cancer: our experience with regimen ifosfamide-etoposide
Tip		članek
Vir		In: Crnjac A, editor. Zbornik predavanj Strokovni simpozij z mednarodno udeležbo ob 50-letnici Oddelka za torakalno kirurgijo; 2004 nov 19; Maribor. Maribor: Splošna bolnišnica Maribor,
Leto izdaje		2004
Obseg		str. 107-15
Jezik		slo
Abstrakt		Background. Introducing lung cancer chemotherapy not routinely used in Slovenia to our department and establishing efficiency and toxicity of such regimen. Patients and methods. From Oct.1998 to Jun. 2001 fifty four patients with small-cell lung cancer (SCLC) were treated with ifosfamide 2,0 g/m2 i.v. on days 1.-3. and etoposide 100 mglm2 i.v. or p.o. on days 1.-3. every 3 weeks. There were 42 male and 12 female, aged 41 to 80 years (median 63), 37 limited disease and 17 extended disease. Performance status (Kamofsky) was >80 in 40 pts, 60-80 in 10 pts, and <60 in 4 pts. Follow-up period was 6 to 39 months. The survival was calculated according to Kaplan-Meier's method, differences were conhrmed by log-rank test. Results. At the end of follow-up period (Dec. 31st, 2001) 16 pts were alive. Most of patients, i.e. 37 pts, received 6 or more planned courses of chemotherapy, other patients received less courses. Median survival of all pts was 11,8 months (limited disease 13,4, and extended disease 9,2 months ) and response rate 77% (10% complete responders and 67% parfial responders ). Toxicity related to chemotherapy was observed in 14 pts: leukopenia 2, cystitis 2, anaemia 4, fever(infection) 2, nausea 4. Following chemotherapy in 25 pts radiotherapy of lung tumor was performed. In 8 pts chemotherapy was changed by cisplatin-etoposide regimen. Conclusion. Chemotherapy regimen ifosfamid-etoposide in our SCLC patients was effective, safe and acceptable in our circumstances.
Deskriptorji		LUNG NEOPLASMS CARCINOMA, SMALL CELL ANTINEOPLASTIC AGENTS, COMBINED ETOPOSIDE IFOSFAMIDE NEOPLASM STAGING SURVIVAL ANALYSIS